Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG CBGJ398X2201

Title
A Phase 2, Multicenter, Open-Label Study Of BGJ398 in Patients with Recurrent Resectable or Unresectable Glioblastoma
Principal Investigator
Jeffrey Raizer
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG CBGJ398X2201
Purpose
The main purpose of this study is to find out if BGJ398 is safe and if it is effective in treating glioblastoma.
Overview
The study drug BGJ398 is a medicine which has not been approved by the Food and Drug Administration (FDA) for the treatment of glioblastoma and is currently not “on the market” (available to buy) in any country. BGJ398 is developed by the company Novartis (the study sponsor). BGJ398 binds and blocks a family of proteins called fibroblast growth factor receptor (FGFR). FGFRs are part of pathway (a series of chemical reactions between proteins) that helps cells to function normally. In some types of cancers, this pathway becomes too active, which can cause tumor cell growth. BGJ398 has been shown to stop cancers in laboratory and animal studies and is being tested in human clinical studies.
Eligibility
Some of the eligibility criteria include:
  • Participants must have glioblastoma that has returned after prior surgery.
  • Participants must have received prior external beam radiotherapy and temozolomide.
  • Participants must be 18 or older.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Study participants will be enrolled in one of two groups. Group 1 will enroll patients who are not eligible for surgical resection of their tumor. Group 2 will enroll patients who will have surgery as part of their routine care. A treatment cycle consists of 28 days. During each 28-day cycle participants will take BGJ398 once a day on days 1 through 21. Participants who will undergo surgery will receive BGJ398 once daily for 5-10 days before surgery. After the surgery, and based on the Study Doctor’s judgment, participants will resume treatment and receive BGJ398 once daily in a 28 days cycle (three weeks on and one week off).
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Jeffrey Raizer

last updated: 22-Nov-14 09:24 PM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.